Advancing Immunohistochemistry (IHC) Through Global Expertise and Integrated Capabilities

Achieving consistent IHC results across regions requires standardized processes, harmonized laboratories, and strong quality control frameworks.

We address this through a globally integrated network of histopathology hubs across North America, Europe, and Asia, all operating under aligned SOPs, validated methods, and accredited quality systems (CAP, CLIA, ISO15189).

This ensures that your assays are executed consistently, regardless of where samples are processed, helping reduce variability and support reliable decision-making.

Yes, we integrate IHC within a broader ecosystem of analytical technologies to provide deeper biological insight. In addition to IHC, your program can benefit from:

• Flow cytometry (including high-parameter capabilities)
• Molecular profiling (NGS, qPCR, ddPCR)
• Ligand-binding assays (MSD, ELISA, ELLA)
• Cytokine and biomarker profiling

By combining these approaches, we help you develop a multi-dimensional understanding of biological mechanisms for more robust and actionable data.

We develop and implement IHC assays using a fit-for-purpose approach, ensuring that each assay is aligned with your study objectives, endpoints, and regulatory expectations.

This includes:

• Assay development, optimization, and validation
• Standardized protocols and quality controls
• Alignment with downstream analysis and reporting requirements

This structured approach ensures your assays deliver reliable, reproducible data that supports clinical and regulatory decision-making.

Yes, our infrastructure is designed to support studies from early development through large-scale, global clinical trials.

Through a network of specialized histopathology hubs and regional laboratories, we provide:

• Scalable sample processing and analysis
• Flexible regional and centralized testing models
• Consistent performance across study phases

This enables seamless progression from early-stage research through to late-phase clinical execution.

Variability in interpretation is a known challenge in IHC. We address this through:

• Standardized staining and analysis workflows
• Digital pathology integration, enabling more objective assessment
• Expert-led review and interpretation

By combining technology with scientific oversight, we ensure consistent, reproducible, and high-confidence results for your program.

We support a wide range of advanced and complex programs, including those involving emerging therapeutic modalities.

We have experience contributing to programs such as gene therapy development, where integrated assay approaches, including IHC, play a critical role in understanding biological response and supporting regulatory submissions.

Our global model is designed to boost both speed and quality for your program. With dedicated IHC and histopathology centers in the United States, Europe, and Asia, we can:

• Reduce sample transit times
• Enable regional processing when needed
• Maintain central oversight and consistency

This approach balances operational efficiency with data harmonization, ensuring timely delivery without compromising quality.

Yes, we support the integration of IHC results with broader datasets across your study. By combining imaging, molecular, and bioanalytical outputs, we help you deliver cohesive, analysis-ready datasets that support informed decision-making. This integrated approach is particularly valuable for programs requiring multi-parameter data analysis.

Engaging early maximizes the value of your IHC strategy and helps set your study up for success. Early collaboration allows you to:

• Align assay strategy with study objectives and clinical endpoints
• Streamline assay development and validation
• Integrate IHC with broader biomarker and analytical plans

The result is reduced risk, fewer delays, and a more robust, decision-ready dataset from the outset.